Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.77 |
| ▸ | CA1 | P00915 | 3/20 | 0.77 |
| ▸ | CA9 | Q16790 | 2/20 | 0.71 |
| ▸ | CA12 | O43570 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.62 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20472197 | 1.00 | CA2 (0.77) | CA2CA1CA9CA12HTT | |
| SCHEMBL7498033 | 0.91 | CA2 (0.83) | CA2CA1CA9CA12HTT | |
| SCHEMBL540915 | 0.86 | CA1 (0.85) | CA2CA1CA9CA12HTT | |
| SCHEMBL11793140 | 0.86 | CA1 (0.85) | CA2CA1CA9CA12HTT | |
| SCHEMBL4823249 | 0.85 | CA2 (0.90) | CA2CA1CA9CA12HTT | |
| SCHEMBL5230151 | 0.83 | CES1 (0.73) | CA2CA1CA9CA12HTT | |
| SCHEMBL98037 | 0.83 | CA2 (0.71) | CA2CA1CA9CA12HTT | |
| SCHEMBL4574130 | 0.83 | CA2 (0.71) | CA2CA1CA9CA12HTT | |
| SCHEMBL21247922 | 0.83 | CA2 (0.71) | CA2CA1CA9CA12HTT | |
| SCHEMBL6577363 | 0.83 | CA2 (0.71) | CA2CA1CA9CA12KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117186049-A | 2, 2-dimethyl-2H chromene derivative containing sulfonamide unit, and preparation method and application thereof | 贵州大学 | 2023-12-08 | — | — | CN | disclosed |
| EP-1218360-B1 | TRIAZINE KINASE INHIBITORS | AMGEN INC (US) | 2008-05-28 | — | — | EP | disclosed |
| US-7074789-B2 | Kinase inhibitors | AMGEN INC. (US) | 2006-07-11 | — | — | US | disclosed |
| US-6881737-B2 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. (US) | 2005-04-19 | — | — | US | disclosed |
| US-20040116388-A1 | triazine compoound inhibitors of enzymes that catalyze phosphoryl transfer and/or that bind ATP/GTP nucleotides | AMGEN INC. | 2004-06-17 | — | — | US | disclosed |
| EP-1390354-A1 | TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS | Amgen Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. | 2003-07-24 | — | — | US | disclosed |
| WO-2002083653-A1 | TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS | AMGEN INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| EP-1218360-A1 | TRIAZINE KINASE INHIBITORS | Amgen Inc., (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001025220-A1 | TRIAZINE KINASE INHIBITORS | AMGEN INC. (US) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | PKD1, PKD2, GLS | CA2 1558/4885CA1 2390/4885CA9 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.